# US 2003/0212019 A1 · Antisense modulation of cot oncogene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212019 A1
- Document ID: US20030212019A1
- Status: Published application
- Kind: A1
- Application number: 10/181,873
- Filed: 2002-12-13
- Published: 2003-11-13
- Earliest claimed: 2002-12-13
- Inventors: C Frank Bennett; Jacqueline Wyatt
- Web page: https://patentgrep.com/patent/US20030212019A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 207/01037: Protein kinase (2.7.1.37) (C12Y207/11001, C12Y207/11008 - C12Y207/11013, C12Y207/11021, C12Y207/11022, C12Y207/11024, C12Y207/11025, C12Y207/1103, C12Y207/12001 take precedence)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/346: having a combination of backbone and sugar modifications
- Y02P 20/582: Recycling of unreacted starting or intermediate materials
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of cot oncogene. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cot oncogene. Methods of using these compounds for modulation of cot oncogene expression and for treatment of diseases associated with expression of cot oncogene are provided.

## Claims

### Claim 1

An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding cot oncogene, wherein said antisense compound specifically hybridizes with and inhibits the expression of cot oncogene.

### Claim 2 (depends on 1)

The antisense compound of claim 1 which is an antisense oligonucleotide.

### Claim 3 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 35, 39, 42, 44, 47, 66, 67, 68, 69, 77, 81, 85, 86, 87 or 88.

### Claim 4 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 5 (depends on 4)

The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

### Claim 6 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

### Claim 7 (depends on 6)

The antisense compound of claim 6 wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.

### Claim 8 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

### Claim 9 (depends on 8)

The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

### Claim 10 (depends on 2)

The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

### Claim 11 (depends on 1)

A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

### Claim 12 (depends on 11)

The composition of claim 11 further comprising a colloidal dispersion system.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

### Claim 14 (depends on 1)

A method of inhibiting the expression of cot oncogene in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of cot oncogene is inhibited.

### Claim 15 (depends on 1)

A method of treating a human having a disease or condition associated with cot oncogene comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of cot oncogene is inhibited.

### Claim 16 (depends on 15)

The method of claim 15 wherein the disease or condition is an immunological disorder.

### Claim 17 (depends on 15)

The method of claim 15 wherein the disease or condition is an inflammatory disorder.

### Claim 18 (depends on 15)

The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

### Claim 19 (depends on 18)

The method of claim 18 wherein the hyperproliferative disorder is cancer.
